Antiretroviral drugs and therapy (ART)

This publication provides guidance on the public health response to pretreatment HIV drug resistance (HIVDR) to non-nucleoside reverse-transcriptase inhibitors (NNRTIs) among people without prior antiretroviral (ARV) drug exposure or people with prior ARV exposure who are initiating or reinitiating first-line antiretroviral therapy (ART).

The aim of this review was to determine if packaged interventions, which include enhanced infection prophylaxis, screening, and other elements of care delivered together, can improve outcomes in HIV-positive patients presenting with advanced disease.

The objectives of these guidelines are to provide recommendations outlining a public health approach to managing people presenting with advanced HIV disease, and to provide guidance on the timing of initiation of antiretroviral therapy (ART) for all people living with HIV.

It is estimated that by the end of 2016, nearly 37 million people were living with HIV, of whom 19.5 million were taking life-saving antiretroviral therapy (ART). This number highlights the incredible progress made in expanding access to treatment, but also underscores the effort still required to fully implement the World Health Organization’s (WHO) “treat all” recommendation.

Summary of country mapping exercise: Regional Consultation and Planning Workshop Use of TRIPS Flexibilities to Access Affordable ARVs in Asia. Bangkok, Thailand 29-31 May (2012)

Presentation on Increasing South-South co-operation through the India-Africa partnership and the Global South at Regional Consultation and Planning Workshop “Use of TRIPS Flexibilities to Access Affordable ARVs in Asia” Bangkok 29-31 May 2012

19 July 2015 WHO Satellite Vancouver – IAS 2015 Eighth International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2015), Vancouver, Canada

2016 Conference on Retroviruses and Opportunistic Infections (CROI 2016) February 22-25, 2016 Boston, Massachusetts, at the Hynes Convention Center

The goal of this report is to provide countries and suppliers with estimates of the global market for antiretroviral (ARV) medicines in low- and middle-income countries for 2015–2020. The report includes estimates of the global demand for both active pharmaceutical ingredients and ARV formulations to enable suppliers to manage their manufacturing capacity accordingly.

WHO recommends initiation of ART for all people living with HIV at any CD4 cell count Fixed dose combinations (FDCs) containing TDF/XTC/EFV remain the preferred first line regimen for adults, adolescents and older children For the first time, DTG and EFV400 have been included as alternative first line regimens for adults and adolescents. DRV/r is an alternative option as part of secondline regimens, along with LPV/r and ATV/r.